Achieve Life Sciences reports FY2021 net loss $33.2M; Phase 3 ORCA-2 topline data expected Q2 2022

ACHIEVE LIFE SCIENCES, INC.

Cash, cash equivalents and restricted cash of $43.1M as of Dec 31, 2021.
Total operating expenses for FY2021 were $33.1M; net loss $33.2M.
Initiated Phase 3 ORCA-3 trial; ORCA-2 completed with topline results due Q2 2022.
Entered $25M loan facility with Silicon Valley Bank in December 2021.
FDA accepted IND for cytisinicline in e-cigarette/vaping cessation; Phase 2 ORCA-V1 expected Q2 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.